Mild Cognitive Impairment disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLD018 MIFTS: 50	Mild Cognitive Impairment Categories: Mental diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Mild Cognitive Impairment

MalaCards integrated aliases for Mild Cognitive Impairment:

Name: Mild Cognitive Impairment ¹¹ ⁷⁵ ⁴¹ ¹⁴

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080832

Sources

Summaries for Mild Cognitive Impairment

MedlinePlus: ⁴¹ Some forgetfulness can be a normal part of aging. However, some people have more memory problems than other people their age. This condition is called mild cognitive impairment, or MCI. People with MCI can take care of themselves and do their normal activities. MCI memory problems may include: Losing things often Forgetting to go to events and appointments Having more trouble coming up with words than other people of the same age Memory problems can also have other causes, including certain medicines and diseases that affect the blood vessels that supply the brain. Some of the problems brought on by these conditions can be managed or reversed. Your health care provider can do thinking, memory, and language tests to see if you have MCI. You may also need to see a specialist for more tests. Because MCI may be an early sign of Alzheimer's disease, it's really important to see your health care provider every 6 to 12 months. At this time, there is no proven drug treatment for MCI. Your health care provider can check to see if you have any changes in your memory or thinking skills over time. NIH: National Institute on Aging

MalaCards based summary: Mild Cognitive Impairment is related to dementia and alzheimer disease, familial, 1. An important gene associated with Mild Cognitive Impairment is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Alzheimer's disease and miRNA effects and Presenilin-Mediated Signaling. The drugs Metformin and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and globus pallidus, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: ¹¹ A cognitive disorder that is characterized by objective impairment in cognition with minimal impairment of their capacity to undertake the instrumental activities of daily living.

Wikipedia: ⁷⁵ Mild cognitive impairment (MCI) is a neurocognitive disorder which involves cognitive impairments beyond... more...

Sources

Related Diseases for Mild Cognitive Impairment

Diseases related to Mild Cognitive Impairment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 547)

#	Related Disease	Score	Top Affiliating Genes
1	dementia	32.0	TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
2	alzheimer disease, familial, 1	31.9	TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
3	amyloidosis	31.9	SNCA SERPINA3 PSEN2 PSEN1 MAPT BACE1
4	cerebrovascular disease	31.6	SERPINA3 MIR181C MIR132 MAPT BDNF BACE1
5	anosognosia	31.6	PSEN2 PSEN1 MAPT APOE
6	rem sleep behavior disorder	31.5	SNCA MAPT BCHE APOE
7	sleep disorder	31.4	SNCA BDNF APOE
8	tremor	31.4	SNCA MAPT CNTN2
9	parkinson disease, late-onset	31.4	SNCA SERPINA3 PSEN2 PSEN1 NEFL MIRLET7D
10	parkinsonism	31.4	SNCA PSEN1 MAPT APP APOE
11	apnea, obstructive sleep	31.3	MIRLET7D BDNF APOE
12	subjective cognitive decline	31.3	TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
13	amnestic disorder	31.3	PSEN2 PSEN1 MAPT CHAT BDNF BCHE
14	movement disease	31.3	SNCA SERPINA3 PSEN2 PSEN1 NEFL MIR132
15	stroke, ischemic	31.2	SERPINA3 PSEN1 MAPT CHAT BDNF BACE1
16	vascular dementia	31.2	SNCA SERPINA3 PSEN2 PSEN1 NEFL MIR15B
17	down syndrome	31.0	SERPINA3 PSEN1 MAPT CHAT BDNF BACE1
18	arteries, anomalies of	31.0	SERPINA3 MIRLET7D MIR15B MIR132 APOE
19	alzheimer disease 2	31.0	SNCA SERPINA3 APP APOE
20	psychotic disorder	31.0	SERPINA3 PSEN1 MIRLET7D MIR132 BDNF APP
21	mood disorder	31.0	SERPINA3 MIRLET7D MIR132 BDNF
22	dementia, lewy body	31.0	TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
23	bipolar disorder	30.9	MIR132 MAPT BDNF APP APOE
24	alzheimer disease 19	30.9	SERPINA3 PSEN2 PSEN1 APP APOE
25	attention deficit-hyperactivity disorder	30.9	SNCA SERPINA3 MAPT BDNF BCHE APP
26	frontotemporal dementia	30.8	TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
27	essential tremor	30.8	SNCA MAPT BDNF
28	agraphia	30.8	PSEN2 MAPT APOE
29	epilepsy	30.8	MIR132 CNTN2 BDNF APP APOE ADRA2B
30	cerebral amyloid angiopathy, cst3-related	30.8	TREM2 SNCA SERPINA3 PSEN2 PSEN1 MAPT
31	hydrocephalus	30.8	SNCA SERPINA3 PSEN1 MAPT BDNF APP
32	alzheimer disease 10	30.7	MAPT APOE
33	binswanger's disease	30.7	MAPT APP APOE
34	arteriolosclerosis	30.7	SNCA SERPINA3 MAPT APP APOE
35	alzheimer disease 11	30.7	PSEN1 MAPT
36	aphasia	30.7	SNCA PSEN2 PSEN1 NEFL MAPT BDNF
37	choreatic disease	30.7	SNCA BDNF APP
38	cerebral degeneration	30.6	TREM2 SNCA SERPINA3 NEFL MAPT APP
39	multiple system atrophy 1	30.6	SNCA SERPINA3 NEFL MIR132 MAPT CHAT
40	huntington disease	30.6	SNCA SERPINA3 PSEN2 PSEN1 MIR132 MAPT
41	secondary progressive multiple sclerosis	30.6	SERPINA3 NEFL MIR15B MIR132
42	alzheimer disease 3	30.5	PSEN2 PSEN1 BACE1 APP APOE
43	prion disease	30.5	SNCA SERPINA3 PSEN2 PSEN1 MIR132 MAPT
44	normal pressure hydrocephalus	30.5	SNCA SERPINA3 PSEN2 PSEN1 NEFL MAPT
45	prosopagnosia	30.5	PSEN2 MAPT
46	creutzfeldt-jakob disease	30.5	SNCA SERPINA3 PSEN1 MAPT APP APOE
47	alzheimer disease 9	30.4	PSEN1 MAPT APOE
48	nominal aphasia	30.4	SNCA PSEN2 PSEN1 MAPT BCHE APOE
49	amyloidosis, hereditary, transthyretin-related	30.4	SNCA APP APOE
50	eye disease	30.4	SERPINA3 MIRLET7D MIR132 BDNF APP APOE

Graphical network of the top 20 diseases related to Mild Cognitive Impairment:

Sources

Symptoms & Phenotypes for Mild Cognitive Impairment

MGI Mouse Phenotypes related to Mild Cognitive Impairment:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.1	APOE APP BACE1 BDNF CHAT CNTN2
2	homeostasis/metabolism	MP:0005376	10.1	ADRA2B APOE APP BACE1 BCHE BDNF
3	normal	MP:0002873	10.06	APP BACE1 BDNF CHAT MAPT NEFL
4	behavior/neurological	MP:0005386	10	ADRA2B APOE APP BACE1 BDNF CHAT
5	no phenotypic analysis	MP:0003012	9.97	APOE APP BACE1 BDNF MAPT MIRLET7D
6	integument	MP:0010771	9.32	APOE APP BACE1 BDNF DGUOK MAPT
7	taste/olfaction	MP:0005394	9.26	APOE BDNF MAPT SNCA

Sources

Drugs & Therapeutics for Mild Cognitive Impairment

Drugs for Mild Cognitive Impairment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Simvastatin

Approved

Phase 4

79902-63-9

54454

Nimodipine

Approved, Investigational

Phase 4

66085-59-4

4497

Levodopa

Approved

Phase 4

59-92-7, 63-84-3

6047

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Donepezil

Approved

Phase 4

120014-06-4

3152

Vildagliptin

Approved, Investigational

Phase 4

274901-16-5

6918537

Galantamine

Approved

Phase 4

357-70-0, 1953-04-4

9651

Atropine

Approved, Vet_approved

Phase 4

101-31-5, 5908-99-6, 51-55-8

3661 154417 174174

Oxybutynin

Approved, Investigational

Phase 4

5633-20-5

4634

Methylphenidate

Approved, Investigational

Phase 4

113-45-1

4158

Rasagiline

Approved

Phase 4

136236-51-6

3052776

Trazodone

Approved, Investigational

Phase 4

19794-93-5

5533

Spironolactone

Approved

Phase 4

1952-01-7, 52-01-7

5833

Cannabidiol

Approved, Investigational

Phase 4

13956-29-1

521372 644019

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Lithium carbonate

Approved

Phase 4

554-13-2

Aripiprazole

Approved, Investigational

Phase 4

129722-12-9

60795

Nortriptyline

Approved

Phase 4

72-69-5

4543

Midodrine

Approved

Phase 4

133163-28-7, 42794-76-3

4195

Memantine

Approved, Investigational

Phase 4

41100-52-1, 19982-08-2

4054

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Levetiracetam

Approved

Phase 4

102767-28-2

441341 5284583

Rotigotine

Approved

Phase 4

99755-59-6, 92206-54-7

57537 59227

Amitriptyline

Approved

Phase 4

50-48-6

2160

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Rizatriptan

Approved

Phase 4

145202-66-0, 144034-80-0

5078

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Duloxetine

Approved

Phase 4

136434-34-9, 116539-59-4

60835

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Lamotrigine

Approved, Investigational

Phase 4

84057-84-1

3878

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Pramipexole

Approved, Investigational

Phase 4

104632-26-0, 104632-25-9, 104632-28-2

4885 119570 59868

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Zolmitriptan

Approved, Investigational

Phase 4

139264-17-8

60857

Sumatriptan

Approved, Investigational

Phase 4

103628-46-2

5358

Propranolol

Approved, Investigational

Phase 4

318-98-9, 525-66-6

62882 4946

Topiramate

Approved

Phase 4

97240-79-4

5284627

Iodine

Approved, Investigational

Phase 4

7553-56-2

807

Huperzine A

Approved, Experimental

Phase 4

102518-79-6

Choline

Approved, Nutraceutical

Phase 4

62-49-7

305

Tramiprosate

Investigational

Phase 4

3687-18-1

1646

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Corticosterone

Experimental

Phase 4

50-22-6

5753

Cadexomer iodine

Experimental

Phase 4

94820-09-4

Anticholesteremic Agents

Phase 4

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Interventional clinical trials:

(show top 50) (show all 1071)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease	Unknown status	NCT04346862	Phase 4	Acetyl-L-carnitine hydrochloride 500mg;Placebo
2	Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients	Unknown status	NCT00842920	Phase 4	Simvastatin 60 mg;Placebo;Simvastatin 20 mg
3	Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study	Unknown status	NCT02326038	Phase 4	Methylphenidate
4	Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial	Unknown status	NCT02409238	Phase 4	Metformin
5	Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)	Unknown status	NCT00306124	Phase 4	Levodopa
6	Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)	Unknown status	NCT01220622	Phase 4	Nimodipine;Placebo
7	Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study	Unknown status	NCT02190019	Phase 4
8	Effects of Vildagliptin, a DPP-4 Inhibitor, in Elderly Diabetic Patients With Mild Cognitive Impairment	Completed	NCT03819127	Phase 4	Vildagliptin 50 MG Oral Tablet;Metformin Pill
9	Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly	Completed	NCT01951118	Phase 4	Donepezil
10	Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age	Completed	NCT01902004	Phase 4	Escitalopram;Memantine;Placebo
11	Olfactory Deficits in Mild Cognitive Impairment as a Predictor of Improved Cognition on Donepezil	Completed	NCT01845636	Phase 4	Donepezil;Atropine
12	The Depression and Memory Trial	Completed	NCT02590874	Phase 4	Duloxetine;Placebo
13	Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment	Completed	NCT00446485	Phase 4	Ginkgo biloba standardized extract 24/6;Ginkgo Biloba standardized extract 24/6;placebo
14	Genomic Outcomes of Metformin	Completed	NCT02986659	Phase 4	Metformin;Placebo
15	The Efficacy and Safety of Qinggongshoutao Bolus for aMnestic Mild Cognitive Impairment: A 52- Week Randomized, Double-blind, Controlled,Three Arms, Multi-center Study	Completed	NCT02982603	Phase 4	Qinggongshoutao Bolus;Ginkgo Biloba Extract 761;Placebos
16	A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment	Completed	NCT00934375	Phase 4	Aricept (donepezil hydrochloride);placebo
17	Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study	Completed	NCT01046292	Phase 4	Ginkgo biloba
18	Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression	Completed	NCT01658228	Phase 4	Donepezil;Placebo;Citalopram;Venlafaxine
19	A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease	Completed	NCT01519271	Phase 4	Exelon Patch (rivastigmine transdermal system);Placebo Patches
20	Core Temperature During Cold Exposure in Persons With Tetraplegia	Completed	NCT01822535	Phase 4	Midodrine hydrochloride
21	A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia	Completed	NCT03811847	Phase 4	Methylphenidate Extended Release Oral Capsule
22	A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study	Completed	NCT01126424	Phase 4	Solifenacin;Oxybutynin;Placebo
23	A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)	Completed	NCT00293176	Phase 4	Donepezil Hydrochloride;Placebo
24	A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy	Completed	NCT01497652	Phase 4	Rasagiline/Placebo;Rasagiline
25	Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial	Recruiting	NCT04296565	Phase 4
26	Randomized-Controlled Trial of Trazodone on Reducing Plasma sST2 Level and Neurodegeneration Progression in Patients With Amnestic Mild Cognitive Impairment and Obstructive Sleep Apnea	Recruiting	NCT05209035	Phase 4	Trazodone
27	Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease	Recruiting	NCT04522739	Phase 4	Spironolactone;Placebo
28	Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE ε4 Carriers	Recruiting	NCT05022186	Phase 4	Cannabidiol Oil;Homotaurine
29	RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)	Active, not recruiting	NCT05531591	Phase 4	Aripiprazole Augmentation;Bupropion Augmentation;Switch to bupropion;Lithium Augmentation;Switch to nortriptyline
30	Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in a Cohort of Patients With Mild Cognitive Impairment	Active, not recruiting	NCT05594355	Phase 4	TEBOFORTAN
31	Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia	Active, not recruiting	NCT03185208	Phase 4	Lithium Carbonate;Placebo oral capsule
32	Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia	Active, not recruiting	NCT02379156	Phase 4	Midodrine Hydrochloride
33	Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease	Enrolling by invitation	NCT05514106	Phase 4	meta-iodobenzylguanidine (MIBG) (123I)
34	Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record	Enrolling by invitation	NCT02670161	Phase 4	Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
35	DaTSCAN Imaging in Aging and Neurodegenerative Disease	Enrolling by invitation	NCT01453127	Phase 4	I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
36	Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia	Enrolling by invitation	NCT00950430	Phase 4	Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
37	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE)	Not yet recruiting	NCT05041790	Phase 4	Choline Alfoscerate;Placebo
38	Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging	Not yet recruiting	NCT02931136	Phase 4	Huperzine A;Placebo
39	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Mild Cognitive Impairment Patients With Cerebrovascular Disease	Not yet recruiting	NCT05050604	Phase 4	Choline Alfoscerate 400mg;Placebo of Choline Alfoscerate 400mg
40	The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial.	Withdrawn	NCT02982642	Phase 4	1612 capsule;Placebos
41	DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial	Unknown status	NCT01708005	Phase 2, Phase 3	Lecitone®Se-Vitamin D3;Placebo
42	Symptomatic Treatment of Vascular Cognitive Impairment	Unknown status	NCT02098824	Phase 2, Phase 3	Galantamine;Methylphenidate;Placebo
43	Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline in Mild Cognitively Impaired Subjects	Unknown status	NCT03641404	Phase 3
44	Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke	Completed	NCT03815292	Phase 3	MMH-MAP;Placebo
45	The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study	Completed	NCT03682185	Phase 3
46	Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment	Completed	NCT01876823	Phase 2, Phase 3	es-citalopram;Memantine
47	Exercise Training to Improve Cognitive Function	Completed	NCT03824639	Phase 3
48	A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type	Completed	NCT03721705	Phase 3
49	Testosterone Supplementation in Men With MCI	Completed	NCT00539305	Phase 3	testosterone gel;placebo gel
50	The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder	Completed	NCT04318639	Phase 2, Phase 3

Search NIH Clinical Center for Mild Cognitive Impairment

Sources

Genetic Tests for Mild Cognitive Impairment

Sources

Anatomical Context for Mild Cognitive Impairment

Organs/tissues related to Mild Cognitive Impairment:

MalaCards : Brain, Temporal Lobe, Globus Pallidus, Prefrontal Cortex, Subthalamic Nucleus, Cortex, Heart

Sources

Publications for Mild Cognitive Impairment

Articles related to Mild Cognitive Impairment:

(show top 50) (show all 21817)

#	Title	Authors	PMID	Year
1	Classification of Alzheimer's disease stage using machine learning for left and right oxygenation difference signals in the prefrontal cortex: a patient-level, single-group, diagnostic interventional trial. ⁶² ⁴¹	Kim J...Kim JG	36394721	2022
2	Effects of Lactiplantibacillus plantarum OLL2712 on Memory Function in Older Adults with Declining Memory: A Randomized Placebo-Controlled Trial. ⁴¹	Sakurai K...Hisatsune T	36296983	2022
3	Effect of Multimodal Intervention (computer based cognitive training, diet and exercise) in comparison to health awareness among older adults with Subjective Cognitive Impairment (MISCI-Trial)-A Pilot Randomized Control Trial. ⁴¹	Chatterjee P...Singh V	36327345	2022
4	Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment. ⁶²	Chen B...Lai YJ	36018182	2023
5	What Are the Key Diagnostic Cognitive Impairment and Dementia Subtypes and How to Integrate all of the Diagnostic Data to Establish a Diagnosis? ⁶²	Baratono S...Press D	36404034	2023
6	Mild Cognitive Impairment: Diagnosis and Subtypes. ⁶²	Bradfield NI	34549629	2023
7	Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. ⁶²	Sotoudeh H...Singhal A	36388611	2023
8	Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in Parkinson's disease with mild cognitive impairment: an event-related oscillation study. ⁶²	Hunerli-Gunduz D...Yener GG	36395544	2023
9	Machine Learning Model to Predict Diagnosis of Mild Cognitive Impairment by Using Radiomic and Amyloid Brain PET. ⁶²	Ciarmiello A...Alzheimer's Disease Neuroimaging Initiative	36240660	2023
10	Special Issue: Mild Cognitive Impairment. ⁶²	Moore NC	36413419	2023
11	Frequency and correlates of mild cognitive impairment and dementia among the oldest old - Evidence from the representative "Survey on quality of life and subjective well-being of the very old in North Rhine-Westphalia (NRW80+)". ⁶²	Hajek A...Konig HH	36084607	2023
12	Olfactory Function and Diffusion Tensor Imaging as Markers of Mild Cognitive Impairment in Early Stages of Parkinson's Disease. ⁶²	Stewart SA...Good KP	34841903	2023
13	What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. ⁶²	Del Percio C...Babiloni C	36413420	2023
14	Cerebral vasomotor reactivity across the continuum of subjective cognitive impairment, amnestic mild cognitive impairment and probable Alzheimer's dementia: A transcranial Doppler and PET/MRI study. ⁶²	Saka E...Topcuoglu MA	36314070	2023
15	Standardization and Validation of the Flash Visual Evoked Potential-P2 Conversion Scores in the Diagnosis of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia. ⁶²	Arruda JE...Steele J	34994216	2023
16	EEG Resting-State Functional Networks in Amnestic Mild Cognitive Impairment. ⁶²	Caravaglios G...Piccoli T	35758261	2023
17	Neuroimaging-Guided Transcranial Magnetic and Direct Current Stimulation in MCI: Toward an Individual, Effective and Disease-Modifying Treatment. ⁶²	Hanoglu L...Yulug B	34751037	2023
18	CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework. ⁶²	Llano DA...Alzheimer's Disease Neuroimaging Initiative (ADNI)	36368195	2023
19	Social determinants of memory change: A three-year follow-up of the Canadian Longitudinal Study on Aging (CLSA). ⁶²	Stinchcombe A...Hammond NG	36257162	2023
20	Cognitive stimulation and cognitive results in older adults: A systematic review and meta-analysis. ⁶²	Gomez-Soria I...Calatayud E	36116285	2023
21	Predicting time-to-conversion for dementia of Alzheimer's type using multi-modal deep survival analysis. ⁶²	Mirabnahrazam G...Alzheimer's Disease Neuroimaging Initiative	36442416	2023
22	Effectiveness of online-based cognitive intervention in community-dwelling older adults with cognitive dysfunction: A systematic review and meta-analysis. ⁶²	Chae HJ...Lee SH	36468299	2023
23	An explainable Artificial Intelligence approach to study MCI to AD conversion via HD-EEG processing. ⁶²	Morabito FC...Mammone N	34889152	2023
24	An efficient Alzheimer's disease prediction based on MEPC-SSC segmentation and momentum geo-transient MLPs. ⁶²	Thushara A	36375415	2022
25	My Healthy Brain: Rationale and Case Report of a Virtual Group Lifestyle Program Targeting Modifiable Risk Factors for Dementia. ⁶²	Mace RA...Vranceanu AM	35079948	2022
26	Microstate feature fusion for distinguishing AD from MCI. ⁶²	Shi Y...Li T	35911952	2022
27	Differences in Brain Volume by Tooth Loss and Cognitive Function in Older Japanese Adults. ⁶²	Matsuyama Y...Shobugawa Y	35831211	2022
28	[Implementation and Effect of the Multimodal Psychosocial MAKS Intervention in Day Care Centers for People with Cognitive Impairment: Follow-up Results After the End of the RCT]. ⁶²	Gra?el E...Luttenberger K	34560797	2022
29	Altered retinal cerebral vessel oscillation frequencies in Alzheimer's disease compatible with impaired amyloid clearance. ⁶²	Kotliar K...Grimmer T	36174284	2022
30	EEG markers and subjective memory complaints in young and older people. ⁶²	Perez V...Salvador A	36150529	2022
31	Cholesterol dysregulation in peripheral blood mononuclear cells of Alzheimer's disease. ⁶²	Martin-Montes A...Bullido MJ	36334319	2022
32	Is non-invasive brain stimulation effective for cognitive enhancement in Alzheimer's disease? An updated meta-analysis. ⁶²	Simko P...Rektorova I	36215904	2022
33	Multi-label classification of Alzheimer's disease stages from resting-state fMRI-based correlation connectivity data and deep learning. ⁶²	Alorf A...Khan MUG	36423532	2022
34	Association of blood-based biomarkers with radiologic markers and cognitive decline in atrial fibrillation patients. ⁶²	Pala E...Montaner J	36309005	2022
35	Assessment of Alzheimer's Disease Imaging Biomarkers in World Trade Center Responders with Cognitive Impairment at Midlife. ⁶²	Kritikos M...Luft BJ	36398306	2022
36	Mid- and Late-Life Physical Activity and Neuropsychiatric Symptoms in Dementia-Free Older Adults: Mayo Clinic Study of Aging. ⁶²	Krell-Roesch J...Geda YE	36464975	2022
37	Associations among hypertension, dementia biomarkers, and cognition: The MEMENTO cohort. ⁶²	Lespinasse J...MEMENTO study group	36464896	2022
38	Convolutional Neural Networks-Based Framework for Early Identification of Dementia Using MRI of Brain Asymmetry. ⁶²	Herzog NJ...Magoulas GD	36106446	2022
39	Wayfinding and spatial perception among adolescents with mild intellectual disability. ⁶²	Zach S...King A	35510305	2022
40	Separation of memory span and learning rate: Evidence from behavior and spontaneous brain activity in older adults. ⁶²	Chen S...Li J	35922140	2022
41	A 5-year community program in Singapore to prevent cognitive decline. ⁶²	Ng TKS...Mahendran R	35922040	2022
42	A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer's Disease. ⁶²	Tahami Monfared AA...Zhang Q	35960495	2022
43	A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease. ⁶²	Li CH...Lin CH	35965282	2022
44	Neuropsychiatric, neuropsychological, and neuroimaging features in isolated REM sleep behavior disorder: The importance of MCI. ⁶²	Vacca M...Liguori C	36116292	2022
45	Efficacy of ICT-based interventions in improving psychological outcomes among older adults with MCI and dementia: A systematic review and meta-analysis. ⁶²	Domenicucci R...Belacchi C	36343879	2022
46	Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study. ⁶²	Lozupone M...Panza F	36155237	2022
47	Surviving a 400 m Fall on Mount Everest. ⁶²	Deonarain D...Karki P	36109266	2022
48	Brucellosis in older person: a case report from Qatar. ⁶²	Al Hamad HK...Bashir Nemeri O	36286586	2022
49	Graphical methods for understanding changes in states: Understanding medication use pathways. ⁶²	Wise EA...Leoutsakos JM	35894783	2022
50	Impact of constipation on progression of Alzheimer's disease: A retrospective study. ⁶²	Nakase T...Taki Y	35934956	2022

Sources

Genes for Mild Cognitive Impairment

Genes related to Mild Cognitive Impairment (0 elite genes):

(show top 50) (show all 54)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CHAT	Choline O-Acetyltransferase	Protein Coding	24.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
2	ADRA2B	Adrenoceptor Alpha 2B	Protein Coding	19.26	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
3	SERPINA3	Serpin Family A Member 3	Protein Coding	11.16	DISEASES inferred ¹⁴ ¹⁴
4	CNTN2	Contactin 2	Protein Coding	11.14	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
5	DGUOK	Deoxyguanosine Kinase	Protein Coding	10.52	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
6	MIR132	MicroRNA 132	RNA Gene	10.4	DISEASES inferred ¹⁴ ¹⁴
7	APOE	Apolipoprotein E	Protein Coding	9.88	DISEASES inferred ¹⁴
8	APP	Amyloid Beta Precursor Protein	Protein Coding	8.99	DISEASES inferred ¹⁴
9	MAPT	Microtubule Associated Protein Tau	Protein Coding	8.8	DISEASES inferred ¹⁴
10	PSEN1	Presenilin 1	Protein Coding	8.5	DISEASES inferred ¹⁴
11	MIR15B	MicroRNA 15b	RNA Gene	8.46	DISEASES inferred ¹⁴ ¹⁴
12	MIR181C	MicroRNA 181c	RNA Gene	8.34	DISEASES inferred ¹⁴ ¹⁴
13	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	8.18	DISEASES inferred ¹⁴
14	BACE1	Beta-Secretase 1	Protein Coding	8.18	DISEASES inferred ¹⁴
15	SNCA	Synuclein Alpha	Protein Coding	8.04	DISEASES inferred ¹⁴
16	MIRLET7D	MicroRNA Let-7d	RNA Gene	8	DISEASES inferred ¹⁴ ¹⁴
17	BCHE	Butyrylcholinesterase	Protein Coding	7.97	DISEASES inferred ¹⁴
18	NEFL	Neurofilament Light Chain	Protein Coding	7.93	DISEASES inferred ¹⁴
19	PSEN2	Presenilin 2	Protein Coding	7.91	DISEASES inferred ¹⁴
20	TREM2	Triggering Receptor Expressed On Myeloid Cells 2	Protein Coding	7.68	DISEASES inferred ¹⁴
21	ACHE	Acetylcholinesterase (Cartwright Blood Group)	Protein Coding	7.66	DISEASES inferred ¹⁴
22	NRGN	Neurogranin	Protein Coding	7.64	DISEASES inferred ¹⁴
23	MIR22	MicroRNA 22	RNA Gene	7.46	DISEASES inferred ¹⁴ ¹⁴
24	CLU	Clusterin	Protein Coding	7.43	DISEASES inferred ¹⁴
25	CEP85L	Centrosomal Protein 85 Like	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
26	MARCHF6	Membrane Associated Ring-CH-Type Finger 6	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
27	MARS2	Methionyl-TRNA Synthetase 2, Mitochondrial	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
28	OPHN1	Oligophrenin 1	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
29	RAPGEF2	Rap Guanine Nucleotide Exchange Factor 2	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
30	SAMD12	Sterile Alpha Motif Domain Containing 12	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
31	TNRC6A	Trinucleotide Repeat Containing Adaptor 6A	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
32	YEATS2	YEATS Domain Containing 2	Protein Coding	7.41	GeneCards inferred via : Disorders (show sections)
33	SORL1	Sortilin Related Receptor 1	Protein Coding	7.36	DISEASES inferred ¹⁴
34	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	7.36	DISEASES inferred ¹⁴
35	IDE	Insulin Degrading Enzyme	Protein Coding	7.3	DISEASES inferred ¹⁴
36	ABCA7	ATP Binding Cassette Subfamily A Member 7	Protein Coding	7.18	DISEASES inferred ¹⁴
37	MIR342	MicroRNA 342	RNA Gene	7.17	DISEASES inferred ¹⁴ ¹⁴
38	INS	Insulin	Protein Coding	7.17	DISEASES inferred ¹⁴
39	MIR106B	MicroRNA 106b	RNA Gene	7.16	DISEASES inferred ¹⁴ ¹⁴
40	MIRLET7G	MicroRNA Let-7g	RNA Gene	7.11	DISEASES inferred ¹⁴ ¹⁴
41	IL6	Interleukin 6	Protein Coding	7.09	DISEASES inferred ¹⁴
42	TOMM40	Translocase Of Outer Mitochondrial Membrane 40	Protein Coding	7.09	DISEASES inferred ¹⁴
43	CDR1	Cerebellar Degeneration Related 1	Protein Coding	7.02	DISEASES inferred ¹⁴
44	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	7	DISEASES inferred ¹⁴
45	BIN1	Bridging Integrator 1	Protein Coding	7	DISEASES inferred ¹⁴
46	IL1B	Interleukin 1 Beta	Protein Coding	6.99	DISEASES inferred ¹⁴
47	DLG4	Discs Large MAGUK Scaffold Protein 4	Protein Coding	6.95	DISEASES inferred ¹⁴
48	MIR142	MicroRNA 142	RNA Gene	6.87	DISEASES inferred ¹⁴ ¹⁴
49	MIR339	MicroRNA 339	RNA Gene	6.86	DISEASES inferred ¹⁴ ¹⁴
50	NGF	Nerve Growth Factor	Protein Coding	6.81	DISEASES inferred ¹⁴

Sources

Variations for Mild Cognitive Impairment

Sources

Expression for Mild Cognitive Impairment

Search GEO for disease gene expression data for Mild Cognitive Impairment.

Sources

Pathways for Mild Cognitive Impairment

Pathways related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 12)

#	Super pathways	Score	Top Affiliating Genes
1	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.58	APOE APP BACE1 MAPT MIR132 PSEN1
2	Presenilin-Mediated Signaling ⁶⁴	11.89	PSEN2 PSEN1 BACE1 APP
3	Neuroscience ³	11.85	TREM2 SNCA PSEN2 PSEN1 NEFL MAPT
4	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.58	NEFL CHAT BDNF
5	DYRK1A ⁷⁴	11.5	PSEN1 MAPT BACE1 APP
6	p75(NTR)-mediated signaling ⁶¹ Show member pathways Ceramide signalling ⁶⁶ NFG and proNGF binds to p75NTR ⁶⁶	11.49	PSEN1 BDNF APP
7	Neurogenesis regulation in the olfactory epithelium ⁷⁴	11.43	PSEN1 MAPT BDNF APP
8	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.42	MAPT BACE1 APP
9	Alzheimers Disease Pathway ⁶⁴	11.09	PSEN2 PSEN1 MAPT BACE1 APP APOE
10	A-beta Plaque Formation and APP Metabolism ⁶⁵	10.98	PSEN2 PSEN1 BACE1 APP
11	Inclusion body myositis ⁷⁴	10.46	PSEN2 PSEN1 MAPT BACE1
12	Notch Pathway ⁷⁰	10.16	PSEN2 PSEN1

Sources

GO Terms for Mild Cognitive Impairment

Cellular components related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.4	SNCA SERPINA3 MIRLET7D MIR181C MIR15B MIR132
2	early endosome	GO:0005769	10.16	PSEN2 PSEN1 BACE1 APP APOE
3	membrane raft	GO:0045121	10.13	PSEN2 PSEN1 MAPT BACE1 APP
4	neuron projection	GO:0043005	10.06	PSEN1 NEFL MAPT CNTN2 CHAT APP
5	neuronal cell body	GO:0043025	10	APOE BACE1 CNTN2 MAPT PSEN1 PSEN2
6	neuromuscular junction	GO:0031594	9.97	APP NEFL PSEN1 PSEN2
7	synaptic vesicle	GO:0008021	9.96	PSEN2 PSEN1 BDNF BACE1 APP
8	dendritic shaft	GO:0043198	9.95	APP PSEN1 PSEN2
9	gamma-secretase complex	GO:0070765	9.83	PSEN2 PSEN1
10	ciliary rootlet	GO:0035253	9.8	PSEN2 PSEN1 APP
11	main axon	GO:0044304	9.76	MAPT APP
12	growth cone	GO:0030426	9.7	SNCA PSEN2 PSEN1 NEFL MAPT APP
13	axon	GO:0030424	9.5	SNCA PSEN1 NEFL MAPT CNTN2 BDNF

Biological processes related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 29)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10.27	PSEN1 MIR132 MAPT APP APOE
2	neuron projection development	GO:0031175	10.16	MAPT CNTN2 APP APOE
3	protein processing	GO:0016485	10.14	PSEN2 PSEN1 CNTN2 BACE1
4	memory	GO:0007613	10.13	TREM2 PSEN1 MAPT BDNF
5	synapse organization	GO:0050808	10.08	SNCA PSEN1 MAPT APP
6	cellular response to copper ion	GO:0071280	10.04	SNCA BACE1 APP
7	membrane protein ectodomain proteolysis	GO:0006509	10.03	BACE1 PSEN1 PSEN2
8	cellular response to amyloid-beta	GO:1904646	10.01	TREM2 PSEN1 BACE1 APP
9	response to lead ion	GO:0010288	9.97	MAPT BACE1 APP
10	regulation of neuronal synaptic plasticity	GO:0048168	9.95	APOE CNTN2 SNCA
11	cellular response to manganese ion	GO:0071287	9.94	BACE1 APP
12	Notch receptor processing	GO:0007220	9.94	PSEN2 PSEN1
13	positive regulation of amyloid-beta clearance	GO:1900223	9.93	TREM2 APOE
14	amyloid precursor protein catabolic process	GO:0042987	9.93	PSEN2 PSEN1 BACE1
15	amyloid fibril formation	GO:1990000	9.92	SNCA MAPT BACE1 APP
16	regulation of axon diameter	GO:0031133	9.91	NEFL CNTN2
17	amyloid-beta metabolic process	GO:0050435	9.91	PSEN2 PSEN1 BACE1
18	astrocyte activation involved in immune response	GO:0002265	9.9	APP PSEN1
19	negative regulation of blood vessel endothelial cell migration	GO:0043537	9.88	MIR15B MIR132 APOE
20	amyloid-beta formation	GO:0034205	9.85	BACE1 PSEN1 PSEN2
21	negative regulation of neuron apoptotic process	GO:0043524	9.85	APOE BDNF MIR15B MIR181C PSEN1 SNCA
22	smooth endoplasmic reticulum calcium ion homeostasis	GO:0051563	9.81	APP PSEN1
23	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.8	MIR181C MIR15B MIR132
24	negative regulation of astrocyte activation	GO:0061889	9.77	MIR181C TREM2
25	regulation of epidermal growth factor-activated receptor activity	GO:0007176	9.76	PSEN1 APP
26	positive regulation of amyloid fibril formation	GO:1905908	9.73	PSEN1 APP APOE
27	negative regulation of low-density lipoprotein receptor activity	GO:1905598	9.62	PSEN1 APP
28	astrocyte activation	GO:0048143	9.56	TREM2 PSEN1 MAPT APP
29	microglial cell activation	GO:0001774	9.28	TREM2 SNCA MIR181C MAPT APP

Molecular functions related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	amyloid-beta binding	GO:0001540	9.76	TREM2 BCHE BACE1 APOE
2	aspartic endopeptidase activity, intramembrane cleaving	GO:0042500	9.56	PSEN2 PSEN1
3	aspartic-type endopeptidase activity	GO:0004190	9.35	PSEN2 PSEN1 BACE1
4	lipoprotein particle binding	GO:0071813	9.1	TREM2 MAPT APOE